Results 201 to 210 of about 120,449 (305)

Reversal of in vitro cellular MRP1 and MRP2 mediated vincristine resistance by the flavonoid myricetin

, 2005
Jelmer J. van Zanden, Anika de Mul, Heleen M. Wortelboer, Mustafa Usta, Peter J. van Bladeren, Ivonne M.C.M. Rietjens, Nicole H.P. Cnubben   +6 more
openalex   +2 more sources

Innate Immune Cell Infiltration Induced by Polatuzumab Vedotin Contributes to the Antitumor Effect in Mouse Models

eJHaem, Volume 7, Issue 1, February 2026.
ABSTRACT Introduction Polatuzumab vedotin (Pola) is an antibody‐drug conjugate approved for the treatment of diffuse large B‐cell lymphoma (DLBCL). Several reports suggest that the tumor microenvironment influences the outcome of DLBCL treatments; with Pola, however, the link between tumor microenvironment and treatment outcome remains unclear ...
Mayu Tomita, Natsumi Kawasaki, Keigo Yorozu, Sei Shu, Chie Kato, Mitsue Kurasawa, Bansho Masutani, Nicolas Sax, Yoriko Yamashita‐Kashima, Shigeki Yoshiura   +9 more
wiley   +1 more source

Histiocytic Sarcoma Treated With Autologous Stem Cell Transplantation: A Case Report and Literature Review of the Role of Autologous and Allogenic Stem Cell Transplantation. [PDF]

Am J Case Rep
Lee YJ, Baek DW.
europepmc   +1 more source

Supplementary Figure 4 from Vincristine Enhances the Efficacy of MEK Inhibitors in Preclinical Models of KRAS-mutant Colorectal Cancer

Susmita Ghosh, Fan Fan, Reid T. Powell, Jason Roszik, Yong Sung Park, Clifford Stephan, Manu Sebastian, Lin Tan, Alexey V. Sorokin, Philip L. Lorenzi, Scott Kopetz, Lee M. Ellis, Rajat Bhattacharya   +12 more
openalex   +1 more source

Effective Use of Olanzapine for Chemotherapy-Induced Nausea and Vomiting in a Patient Receiving Dose-Adjusted Rituximab, Etoposide, Prednisone, Vincristine (Oncovin®), Cyclophosphamide, and Doxorubicin (R-EPOCH): A Case Report. [PDF]

Cureus
Shimada H, Ohgami M, Kurokawa Y, Tachihara S, Sugaya A.   +4 more
europepmc   +1 more source

Vincristine sulfate liposomal injection for acute lymphoblastic leukemia [Corrigendum]

, 2013
Andrew S. Moore, Trisha Soosay Raj, Amanda Smith   +2 more
openalex   +2 more sources

Robotic Resection of Parapharyngeal Follicular Dendritic Cell Sarcoma With Castleman Disease

The Laryngoscope, Volume 136, Issue 2, Page 798-802, February 2026.
Parapharyngeal follicular dendritic cell sarcoma (FDCS) is rare and may occur with Castleman disease. We describe the successful transoral robotic resection of a parapharyngeal FDCS associated with Castleman disease, highlighting the role of the robotic approach in achieving tissue diagnosis and definitive treatment.
Lily Huang, Aman M. Patel, Timothy Chao, Ryan M. Carey   +3 more
wiley   +1 more source

Comprehensive pharmacovigilance of phytoalkaloid chemotherapeutics: Signal detection and time-to-onset analysis based on FAERS. [PDF]

Medicine (Baltimore)
Song B, Zhang Y, Wang L, Hu J.
europepmc   +1 more source

Natural Products in Cancer Prevention and Therapy: Current Challenges and Future Directions

MedComm, Volume 7, Issue 2, February 2026.
Natural products play a pivotal role in cancer therapy. They induce cancer cell death by reprogramming four metabolic pathways while precisely targeting the tumor microenvironment and immune cells. These compounds not only leverage novel delivery systems for innovative applications but also demonstrate unique therapeutic efficacy across clinical stages:
Ruimiao Qian, Jun Ge, Ni Fan, Zheng Sun, Chengcheng Zhao, Yujiao Sun, Yingpeng Li, Yunfei Li, Hui Fu   +8 more
wiley   +1 more source

Children and Adolescents With Localised Non‐Rhabdomyosarcoma Soft Tissue Sarcoma: Results of the CWS‐96 and CWS‐2002P Prospective Trials With Reclassification of the Trial Data Incorporating the Recent Soft Tissue Sarcoma Registry

Pediatric Blood &Cancer, Volume 73, Issue 2, February 2026.
ABSTRACT Background Here we report the results of the first comprehensive European trials for all soft tissue sarcoma entities, which aimed to develop a new risk stratification system, limit radiotherapy and chemotherapy for low‐/standard‐risk patients, and evaluate different chemotherapy regimens for high‐risk patients.
Amadeus T. Heinz, Anton Schönstein, Ewa Koscielniak, Martin Ebinger, Jörg Fuchs, Semi Harrabi, Christian Vokuhl, Roland Imle, Sabine Stegmaier, Ines B. Brecht, Gustaf Ljungman, Hanna Juntti, Ruth Ladenstein, Bernarda Kazanowska, Thomas Klingebiel, Kristian W. Pajtler, Monika Sparber‐Sauer   +16 more
wiley   +1 more source